The official disclosure period of the third quarterly report is coming! The net profit of some pharmaceutical companies increased sharply year-on-year

【Pharmaceutical Network Industry News】After the National Day, the official disclosure period of the third quarterly report of listed companies is coming
.
On the evening of October 9, two listed companies have released the third quarter report of 2022 in advance, one of which is a pharmaceutical company, namely Kangyuan Pharmaceutical
.
Kangyuan Pharmaceutical's report for the third quarter of 2022 shows that it achieved operating income of 1.
028 billion yuan, an increase of 26.
25% year-on-year; Net profit of 70.
2172 million yuan, an increase of 47.
48% year-on-year; Basic earnings per share were RMB0.
12
.
According to the data, Kangyuan Pharmaceutical is a company that takes the development of traditional Chinese medicine as the main body and actively lays out chemical drugs, biological drugs and other fields, and the company's main business involves the research and development, production and sales
of drugs.
Due to the company's eye-catching performance, Zheshang Securities issued a research report on October 09 that it gave Kangyuan Pharmaceutical an overweight rating
.
The reasons for the rating mainly include 5 aspects: performance: the recovery under the epidemic situation is good, and it is optimistic about the release of the Q4 peak season performance; Growth analysis: oral liquid line continued to increase at a high rate, and East China recovered well from the perspective of product lines; Profitability: Short-term pressure on gross profit margin, R&D expense ratio rise; Operating quality analysis: operating cash flow far exceeds net profit, and operational efficiency is significantly improved; Strategic analysis: Channel management continues to advance to help achieve equity incentive goals
.
Risk Warning: The risk of the epidemic affecting hospital-side sales; The risk that the marketing reform will not progress as expected; The risk
that the pace of new drug development will not be as fast as expected.
It is understood that the listed companies that disclose the three quarterly reports first are generally "excellent students", in addition to Kangyuan Pharmaceutical, according to the pre-disclosure schedule of the listed companies' 2022 third quarter reports, in October, there are also a number of pharmaceutical companies such as Wantai Biological, Kelun Pharmaceutical, Zuoli Pharmaceutical, Kaipu Biological, Enhua Pharmaceutical and so on will successively release three quarterly reports
.
The industry said that through the three quarterly reports, the performance growth of listed companies in the first three quarters and the overall development of the industry can be viewed, in addition, the recent disclosure of the first three quarters of the performance forecast is also an important factor
for investors to judge the growth of the industry.
As of noon on October 9, according to the statistics of Oriental Wealth Choice, 90 A-share stocks have made a preview
of the performance of the first three quarters of this year.
According to the statistics of the lower limit of the net profit attributable to the forecast, 63 stocks achieved a year-on-year increase in net profit, accounting for 70%.

There are nearly 20 companies whose net profit growth is expected to exceed 100%.

In the pharmaceutical industry, Kaipu Biological, Huada Intelligent Manufacturing and other expected net profits are expected to increase by more than 100%, of which Huada Intelligent Manufacturing is expected to achieve a net profit attributable to the mother in the first three quarters of this year of 1.
893 billion yuan to 2.
023 billion yuan, an increase of 311.
80% to 340.
08%
year-on-year.
In addition, Kelun Pharmaceutical, Zuoli Pharmaceutical, Oppmai, Micro Electrophysiology and other first three quarters of this year are also expected to achieve good results
.
Guojin Securities newly released research report said that the market entered the third quarter reporting window, the bank expects that the performance of the medical sector in the third quarter will be significantly improved relative to the second quarter, and it is recommended to pay attention to the more bright sectors with Q3 performance expectations, such as some medical devices and equipment, head medical beauty, ophthalmic oral consumer devices, HPV vaccines, etc
.
Ping An Securities also believes that the performance of the pharmaceutical industry in the third quarter is expected to achieve accelerated growth, and recommends paying attention to three main lines, including the traditional Chinese medicine sector, the innovation industry chain, and some other tracks with high prosperity and high barriers, such as featured APIs, preparation exports and nuclear medicine
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.